

Supplementary

Table S1 Clinicopathological characteristics of clinical samples with OV in tissue

Characteristics	No. cases
Age (years)	
≤50	48
>50	22
Gender	
Female	70
Histologic grade	
Moderate and well	42
Poor	28
Anatomic Site	
Ovary	27
Fallopian tube	35
Peritoneum	8

OV, ovarian cancer.

Table S2 Clinicopathological characteristics of clinical samples with OV

Patient	Gender	Age (years)	Anatomic site
1	Female	64	Ovary
2	Female	54	Fallopian tube
3	Female	70	Peritoneum

OV, ovarian cancer

Table S3 Univariate and multivariate analysis of various factors associated with OS in OV patients

Characteristics	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P value	HR (95% CI)	P value
PPL expression				
High expression	9.66 (1.289–72.361)	0.027	7.111 (0.877–57.668)	0.066
Age (years)				
>50	1.759 (0.703–4.585)	0.221	–	–
Histopathological type				
Mucous carcinoma	2.800 (0.856–9.156)	0.088	–	–
FIGO stage				
III + IV	1.622 (0.683–3.852)	0.272	–	–
Histologic grade				
Poor	1.181 (0.488–2.858)	0.711	–	–
Lymph node metastasis				
Yes	3.00 (1.145–7.884)	0.025	1.738 (0.619–4.883)	0.293

OS, overall survival; OV, ovarian cancer; PPL, periplakin; HR, hazard ratio.




Figure S1 Multi-tumor screening of PPL expression and prognosis of patients in TCGA database. (A) PPL expression in 31 malignant tumor tissues; (B) survival analysis of PPL on the prognosis of multiple tumor patients, indicating that the survival of patients with high PPL expression and LGG in OV was poor, and the survival of patients with high expression PPL in ACC and SARC was better. PPL, periplakin; TCGA, The Cancer Genome Atlas; ACC, adenoid cystic carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, low-grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian cancer; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymic carcinoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.